94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Toshio Shimizu1,2*
John Powderly3
Albiruni Abdul Razak4
Patricia LoRusso5
Kathy D. Miller6
Steven Kao7
Sarah Kongpachith8
Catherine Tribouley8
Michelle Graham8Brian Stoll8Maulik Patel8
Mohammad Sahtout8Martha Blaney8
Rachel Leibman8Talia Golan9,10
Anthony Tolcher11- 1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
- 2Department of New Experimental Therapeutics and International Cancer New Drug Development Center, Kansai Medical University Hospital, Osaka, Japan
- 3Carolina BioOncology Institute, Huntersville, NC, United States
- 4Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, Canada
- 5Yale Cancer Center, Yale University, New Haven, CT, United States
- 6Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States
- 7Department of Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW, Australia
- 8AbbVie Bay Area, South San Francisco, CA, United States
- 9Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
- 10Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel
- 11New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United States
By Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller KD, Kao S, Kongpachith S, Tribouley C, Graham M, Stoll B, Patel M, Sahtout M, Blaney M, Leibman R, Golan T and Tolcher A (2024) Front. Oncol. 14:1376551. doi: 10.3389/fonc.2024.1376551
In the published article, there were errors in Figure 4 as published. The graph included incorrect labeling of livmoniplimab doses for a few patients, including for the patient with deepest response (corrected from livmoniplimab 100mg to livmoniplimab 1500mg) in Figure 4B. The corrected Figure 4 and its caption appear below.
Figure 4
Figure 4. Percentage change in target lesion sum diameter measurements from baseline over time per investigator assessment in response-evaluable set (efficacy-evaluable patients defined as patients who have received at least 1 dose of study drug and have either had at least 1 postdose tumor assessment or discontinued treatment due to AE, progressive disease, or death); per RECIST v1.1 and iRECIST. (A) Livmoniplimab monotherapy (Q2W) cohorts (N=22). (B) Livmoniplimab (Q2W) and budigalimab combination therapy cohorts (N=34). → Denotes patients still on treatment. One patient did not have on-study tumor measurement data due to early death. AE, adverse event; iRECIST, modified RECIST v1.1 criteria for immune-based therapeutics; Q2W, once every 2 weeks; RECIST, Response Evaluation Criteria in Solid Tumors.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: advanced solid tumors, TGF-ß1, GARP, immunotherapy, anti-PD-1 antibody, combination drug therapy, investigational therapies, tumor microenvironment (TME)
Citation: Shimizu T, Powderly J, Abdul Razak A, LoRusso P, Miller KD, Kao S, Kongpachith S, Tribouley C, Graham M, Stoll B, Patel M, Sahtout M, Blaney M, Leibman R, Golan T and Tolcher A (2025) Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors. Front. Oncol. 14:1544394. doi: 10.3389/fonc.2024.1544394
Received: 12 December 2024; Accepted: 19 December 2024;
Published: 31 January 2025.
Edited and Reviewed by:
Cory L. Brooks, California State University, Fresno, United StatesCopyright © 2025 Shimizu, Powderly, Abdul Razak, LoRusso, Miller, Kao, Kongpachith, Tribouley, Graham, Stoll, Patel, Sahtout, Blaney, Leibman, Golan and Tolcher. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Toshio Shimizu, dG9zc2hpbWlAbmNjLmdvLmpw